{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psychosis-schizophrenia/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"594160f5-1a9b-56f0-952c-5c400ea28785","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 4a37fc9f-d783-45fd-b2d3-c07e4840f362 --><h2>Changes</h2><!-- end field 4a37fc9f-d783-45fd-b2d3-c07e4840f362 -->","summary":null,"htmlStringContent":"<!-- begin item 7615fe06-eb5e-4680-81b5-6aca6197e071 --><!-- begin field e72af7b7-1df6-48c4-82e9-b98cec28316f --><p><strong>November 2020 </strong>— minor update. New recommendation to monitor blood concentration of some antipsychotics has been added to the Monitoring section.</p><p><strong>August 2020 </strong>— minor update. New NICE quality standard QS194 added.</p><p><strong>June 2020 </strong>— minor update. Adverse effects of quetiapine have been added to the Prescribing section in line with the revised manufacturer's SPC.</p><p><strong>January 2020 </strong>— reviewed. A literature search was conducted in January 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field e72af7b7-1df6-48c4-82e9-b98cec28316f --><!-- end item 7615fe06-eb5e-4680-81b5-6aca6197e071 -->","topic":{"id":"9b90da89-2ffd-5b6a-9fc6-ea342404d5d8","topicId":"fd02ebc3-0f02-42b5-8737-e0608ca4330d","topicName":"Psychosis and schizophrenia","slug":"psychosis-schizophrenia","lastRevised":"Last revised in November 2020","chapters":[{"id":"d60310a0-752b-5399-8488-a567bf6a3925","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"10869ad6-510d-54db-bc6a-ce3618a1c478","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1025e31f-c89d-5344-b4ae-d5e8950a5c0e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"594160f5-1a9b-56f0-952c-5c400ea28785","slug":"changes","fullItemName":"Changes"},{"id":"e20c0ce8-30f6-5e09-81d1-3e6005f85efe","slug":"update","fullItemName":"Update"}]},{"id":"4c4f0990-85fa-5fc4-9a58-9f02a868a971","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02637a5f-4552-5e73-9245-cf480497e9a5","slug":"goals","fullItemName":"Goals"},{"id":"8c88de52-9655-52d8-b302-67641ae05beb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c6754da2-fd29-5d45-8097-40b8ec0589cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"31a210b8-403b-5530-b1ea-0b44a2595f07","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5630117-b04c-558a-b516-41c3eab9adbd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e9e078fd-a616-51bf-944f-2efbb2a01feb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"99d1cff5-adca-5573-9fa8-58c2e9f937e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23ac3781-557a-57b8-95b5-83db37a53fda","slug":"definition","fullItemName":"Definition"},{"id":"3e7238cc-23d8-56f6-a8af-255ed6a876d7","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"9576e7c9-3a1e-57d3-bb86-a4e5e10462e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b79b29b0-d7ad-5bad-87fd-e5a48ced5427","slug":"course-prognosis","fullItemName":"Course and prognosis"},{"id":"598444d7-6337-5133-a088-176b1f83ab01","slug":"complications","fullItemName":"Complications"}]},{"id":"a913b80f-eec4-5c47-9d9c-0b20f4648b73","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7897095-2be8-5df7-a7e3-c1060d4a453a","slug":"identifying-someone-at-risk-of-a-psychotic-disorder-or-experiencing-their-first-episode-of-psychosis","fullItemName":"Identifying someone at risk of a psychotic disorder or experiencing their first episode of psychosis"},{"id":"a8f36210-9cb6-590b-8e3d-7ddbc6d31e88","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f86ff69c-c33e-5b8c-affa-04759f25bf5a","fullItemName":"Management","slug":"management","subChapters":[{"id":"34c0807e-9463-536b-9ff4-c3537046a6ba","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"468f8b6f-bc79-5ecd-b1c2-d7ff27721abe","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"30f16f24-0127-53b7-bd08-c679a189090b","slug":"the-routine-schizophrenia-or-psychosis-review","fullItemName":"Scenario: The routine schizophrenia or psychosis review"},{"id":"c20919b9-2e4c-5c56-b3cd-7fb432199a8b","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f78f8497-f98b-5445-82fe-23a4ced38576","slug":"available-antipsychotics","fullItemName":"Available antipsychotics"},{"id":"05e42d64-ee5a-5c2b-8817-5fc77abb19ec","slug":"adverse-effects","fullItemName":"Adverse effects"},{"id":"25b3e7d5-bc3d-5749-9304-a717c1f4e386","slug":"interactions","fullItemName":"Interactions"},{"id":"ed339043-f5e2-5209-9ba0-cb06890e1050","slug":"monitoring","fullItemName":"Monitoring"}]},{"id":"7ae82132-000d-507c-b73d-542c43656041","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1bf0a6af-76cf-5f6b-b7fb-4c746ff0f413","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"49b46ed4-7209-5c01-b07f-54117f9ad3c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4647644-8726-5bfc-b471-6e157c3f10a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a31ae673-4520-58d5-95ee-db2395fb5238","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3beebe4c-a826-5b46-a8cd-a97fe8ec3b8b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"aaaadecf-036b-531f-a8bf-75fccd84219f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49078833-deae-54f3-ad89-562370e4d181","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1025e31f-c89d-5344-b4ae-d5e8950a5c0e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"48f935f5-c91d-59cc-a545-96c7cc6d8464","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 0388d4e2-a4b0-4cce-965d-f1dc908bc5f1 --><h3>Previous changes</h3><!-- end field 0388d4e2-a4b0-4cce-965d-f1dc908bc5f1 -->","summary":null,"htmlStringContent":"<!-- begin item 64456f27-279f-4314-8bd2-8e4c1dbdbc7b --><!-- begin field ca0c7daf-26bb-4602-bde7-807395edbd95 --><p><strong>December 2016</strong> — minor update.</p><ul><li>Drug Reaction associated with Eosinophilia and Systemic Symptoms (DRESS) has been added as an adverse effect of olanzapine in line with the manufacturer's Summary of Product Characteristics. </li><li>The section on adverse effects has been updated in line with the manufacturer's Summary of Product Characteristics for Seroquel<sup>®</sup>.</li></ul><p><strong>October 2016</strong> — minor update. Information added on reported cases of misuse and abuse with quetiapine in line with the manufacturer's Summary of Product Characteristics.</p><p><strong>February 2015</strong> — minor update. Diplopia added as an uncommon adverse effect of aripiprazole based on an update to the Summary of Product Characteristics (SPC).</p><p><strong>April 2014 to June 2014</strong> — reviewed. A literature search was conducted in March 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. The following changes have been made in line with the NICE guideline <em>Psychosis and schizophrenia in adults: treatment and management</em>:</p><ul><li>A new section on how to identify someone at risk of developing a psychotic disorder has been included.</li><li>The management sections have been updated to include the management of people who are at risk of developing a psychotic disorder.</li></ul><p><strong>March 2014 </strong>— minor update. Links in the routine review scenario to incapacity benefit have been changed to Employment Support Allowance.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012 </strong>— minor update. New information about the rare association of quetiapine with diabetic ketoacidosis has been added ABPI Medicines Compendium, 2011. Issued in February 2012.</p><p><strong>January 2012 </strong>— minor update. Relevant information from the Medicines and Healthcare products Regulatory Agency (MHRA) safety alert about a risk of extra-pyramidal effects or withdrawal symptoms (or both) in newborns after maternal use of antipsychotics during the third trimester of pregnancy has been added to this topic. Issued in January 2012.</p><p><strong>May 2011 </strong>— minor update. Relevant recommendations from the NICE guideline <em>Psychosis with coexisting substance misuse </em>have been incorporated into this topic. The 2011/2012 QOF indicators have also been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>October 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded prescribers that smoking induces metabolism of olanzapine and clozapine, so stopping smoking can increase levels of these drugs, possibly causing increased adverse effects. Issued in October 2009.</p><p><strong>July to October 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been no major changes to the recommendations.</p><p><strong>April 2009 </strong>— updated to include the indicators related to schizophrenia in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract in the <em>Goals and outcome measures </em>section. Issued in May 2009.</p><p><strong>March 2009 </strong>— text updated to include new advice from the Medicines and Healthcare products Regulatory Agency (MHRA) on the increased risk of stroke with atypical antipsychotics in the elderly. Risperidone has been reclassified as a black triangle drug by the Medicines and Healthcare products Regulatory Agency (MHRA) after the granting of a new narrow indication for short-term use for the treatment of dementia-related behavioural disturbances. Issued in April 2009.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued in September 2008.</p><p><strong>July to September 2006 </strong>— reviewed. Validated in December 2006 and issued in January 2007.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— minor update. Quetiapine starter packs have been discontinued and the prescriptions have accordingly been updated. Issued in July 2005.</p><p><strong>April 2004 </strong>— updated to include recent advice from the Committee on Safety of Medicines that risperidone and olanzapine should, where possible, be avoided in patients with a history of stroke or transient ischaemic attacks. Issued in July 2004.</p><p><strong>March 2003 </strong>— written. Validated in June 2003 and issued in July 2003.</p><!-- end field ca0c7daf-26bb-4602-bde7-807395edbd95 --><!-- end item 64456f27-279f-4314-8bd2-8e4c1dbdbc7b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}